Dynamite News Study finds how mRNA used to target Alzheimer's disease
Researchers at The Florey have created a method using mRNA technology to specifically target the harmful protein tau, which accumulates in dementia patients suffering from Alzheimer's disease and other conditions. Read further on Dynamite News:
Melbourne: Researchers at The Florey have created a method using mRNA technology to specifically target the harmful protein tau, which accumulates in dementia patients suffering from Alzheimer's disease and other conditions.
mRNA has primarily been utilised in vaccinations up to this point, notably those meant to combat COVID-19.
The Florey is now recognised as a major leader in the field of mRNA thanks to new research that was published today in Brain Communications. Dr Rebecca Nisbet is leading the technology in this new direction.
"This is the first time mRNA has been explored for use in Alzheimer's disease," Dr Nisbet said. "Our work in cell models demonstrates that this technology can serve purposes other than vaccine development."
Also Read |
Healthy lifestyle could help offset genetic risk of dementia
She likened mRNA to an instruction manual for cells. "Once delivered to the cell, the cell reads the mRNA and makes an antibody."
The Florey team used mRNA to instruct cells in cell models to create RNJ1, an antibody Dr Nisbet developed to target tau, a protein that clumps in the brain cells of dementia patients.
"This is the first time, to our knowledge, a tau antibody has been able to directly engage tau within the cell."
First author on the paper, PhD student Patricia Wongsodirdjo said: "Our technique can be applied to any therapeutic antibody, and we envision that this strategy, when combined with nanoparticle packaging, will enhance targeting of toxic molecules in the brain and improve patient outcomes compared to conventional strategies."
Also Read |
Australia's Victoria extends Melbourne COVID-19 lockdown for 2nd week
Dr Nisbet said RNJ1 still needed further research. She said emerging Alzheimer's treatments, such as lecanemab, which is approved in the USA and under consideration in Australia, are promising but expensive to make and are not an efficient way of getting an active antibody into brain cells.
"With conventional antibodies, such as lecanemab, the small amount of antibody that does enter the brain can remove some harmful plaque that lies outside our brain cells but can't access toxic proteins such as tau, which is located in our brain cells," Dr Nisbet said. (ANI)